Two recent studies analyzed the renal effects of medications for type 2 diabetes, one finding lower rates of acute kidney injury with sodium-glucose co-transporter-2 inhibitors and the other finding reduced onset of macroalbuminuria with liraglutide.
Recent studies looked at light therapy for depression and diabetes, seasonal variation in glycemic control, and associations between outdoor sunlight and temperature and metabolism.
Recent studies looked at stroke risk among patients with diabetes and the effects of hypertension treatment, acetaminophen use, gout, and obesity.
The effects of adding liraglutide to insulin treatment were assessed by multiple studies published in the past month.
The effects of sodium-glucose cotransporter-2 (SGLT-2) inhibitors on heart failure, in patients with and without diabetes, were the focus of three analyses published in the past month, two on dapagliflozin and one on canagliflozin.
A study compared patients' HbA1c levels on human and analogue insulins, a report analyzed insulin price changes between 2012 and 2016, and politicians asked pharma companies for answers.
In the past month, a new meta-analysis compared metformin to other diabetes drugs, and the FDA expanded metformin's indications in patients with reduced kidney function.
Metformin—including its use, effects, and mechanisms—was the focus of some research published in the past month.
One study found that personalized text messaging improved patients' self-management while another looked at the potential value of providing social comparisons to other patients' diabetes control.
One recent study found overtreatment of type 2 diabetes among elderly patients, while another looked at how many patients with diabetes would be referred to a liver specialist under proposed European guidelines.